Interpace Biosciences (NASDAQ: IDXG) Growth Capacity Aided by $20 Million Investment Agreement with Major Capital Partners
Leading private equity firms 1315 Capital and Ampersand Capital Partners’ recent investment agreement with Interpace signal a “clear vote of confidence” Company’s business units, Interpace Diagnostics and Interpace Pharma Solutions, support the biotech and pharmaceutical sectors as they seek to improve early cancer diagnosis and promote increasingly effective therapies Life sciences industry forecast to reach $33.2 billion by 2024, experiencing an 11.5% CAGR over 5-year period Interpace Biosciences (NASDAQ: IDXG), an evolving leader in the life sciences industry, recently entered into a $20 million investment agreement with two leading private equity firms investing in laboratory services (http://ibn.fm/G8cUU). The Series B Preferred…
